Table 2.
Baseline Clinical Characteristics Depending on Flare.
| Clinical feature | Flare (+) (n=29) |
Flare (−) (n=136) |
p | |||
|---|---|---|---|---|---|---|
| Sex (female), n (%) | 26 (89.7) | 127 (93.3) | 0.38 | |||
| Age (years) | 43.1±15.2 | 47.0±14.1 | 0.13 | |||
| Disease duration (months) | 115.5±104.8 | 160.1±220.2 | 0.32 | |||
| WBC (×103/μL) | 4.7±2.1 | 6.1±2.3 | <0.01 | |||
| Hb (g/dL) | 12.0±1.5 | 12.1±1.6 | 0.47 | |||
| Plt (104/μL) | 22.7±8.6 | 22.3±7.2 | 0.59 | |||
| SLEDAI | 2.3±3.4 | 2.7±3.6 | 0.55 | |||
| Proteinuria (g/gCr) | 0.2±0.6 | 0.3±1.0 | 0.44 | |||
| eGFR (mL/min) | 84.1±20.9 | 72.9±24.7 | 0.10 | |||
| CRP (mg/dL) | 0.4±1.3 | 0.3±0.6 | 0.53 | |||
| CH50 (U/mL) | 34.9±10.7 | 36.5±10.7 | 0.42 | |||
| Anti-Sm antibody positive, n (%) | 5 (17.2) | 11 (8.1) | 0.13 | |||
| Anti-dsDNA antibody (IU/mL) | 14.7±24.4 | 13.7±23.6 | 0.77 | |||
| Anti-cardiolipin antibody (IU/mL) | 13.3±11.4 | 12.2±12.3 | 0.46 | |||
| Lupus anticoagulant positive, n (%) | 8 (27.6) | 32 (23.5) | 0.64 | |||
| PSL use, n (%) | 24 (82.8) | 123 (90.4) | 0.22 | |||
| PSL (mg/day) | 5.1±4.0 | 6.0±4.3 | 0.27 | |||
| HCQ use, n (%) | 1 (3.4) | 30 (22.1) | <0.01 | |||
| IS use, n (%) | 1 (3.4) | 16 (11.7) | 0.18 | |||
| HCQ-monotherapy, n (%) | 0 (0) | 4 (2.9) | 0.35 | |||
| HCQ+PSL, n (%) | 0 (0) | 10 (7.3) | 0.13 | |||
| HCQ+PSL+IS, n (%) | 1 (3.4) | 16 (11.7) | 0.18 | |||
| Drug free, n (%) | 5 (17.2) | 5 (3.6) | 0.02 | |||
| PSL-monotherapy, n (%) | 7 (24.1) | 42 (30.9) | 0.67 | |||
| PSL+IS, n (%) | 16 (55.2) | 55 (40.4) | 0.14 |
Values indicate mean±standard deviation unless otherwise indicated.
WBC: white blood cells, Hb: hemoglobin, Plt: platelets, SLEDAI: Systemic Lupus Erythematosus Disease Activity Index, GFR: glomerular filtration rate, CRP: c-reactive protein, PSL: prednisolone, HCQ: hydroxychloroquine, IS: immunosuppressant